Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | GALR1 | P47211 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542548 | 0.89 | TACR1 (0.49) | PDE4APDE4BPDE4CPDE4DTACR1 | |
| SCHEMBL4160740 | 0.87 | TACR1 (0.48) | PDE4APDE4BPDE4CPDE4DTACR1 | |
| SCHEMBL4166875 | 0.85 | TACR1 (0.48) | PDE4APDE4BPDE4CPDE4DTACR1 | |
| SCHEMBL16874615 | 0.84 | KDM4E (0.47) | PDE4APDE4BPDE4CPDE4DTACR1 | |
| SCHEMBL4159626 | 0.83 | HSD11B1 (0.56) | TACR1RORCATMALOX15TSHR | |
| SCHEMBL4162177 | 0.82 | ALDH1A1 (0.50) | TACR1GPR119STSCCR5 | |
| SCHEMBL4551945 | 0.82 | TACR1 (0.53) | TACR1GPR119RORCATMPTGDR2 | |
| SCHEMBL31693832 | 0.82 | TACR1 (0.53) | TACR1GPR119RORCATMPTGDR2 | |
| SCHEMBL4416844 | 0.81 | TACR1 (0.48) | PDE4APDE4BPDE4CPDE4DTACR1 | |
| SCHEMBL10306289 | 0.80 | TACR1 (0.50) | TACR1GPR119ATMALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | ALVARO GIUSEPPE | 2009-07-30 | — | — | US | disclosed |
| US-20070073061-A1 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073061-A1 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | SLC6A4, OPRL1, HCRTR1 | PDE4A 2612/4885PDE4B 2645/4885PDE4C 3397/4885 |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | SLC6A4, OPRL1, HCRTR1 | PDE4A 2612/4885PDE4B 2645/4885PDE4C 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.